Alprostadil topical - Apricus Biosciences

Drug Profile

Alprostadil topical - Apricus Biosciences

Alternative Names: Alprox-TD; Befar; Cold Chain Vitaros; Femprox; RayVa; Room Temperature Vitaros; Topical ED treatment - Apricus; Virirec; Vitaros; Vytaros; WC-3036

Latest Information Update: 29 Dec 2016

Price : $50

At a glance

  • Originator NexMed
  • Developer Apricus Biosciences; Ferring Pharmaceuticals; Laboratoires Majorelle; Recordati
  • Class Erectile dysfunction therapies; Monounsaturated fatty acids; Muscle relaxants; Peripheral vasodilators; Prostaglandins; Small molecules
  • Mechanism of Action Prostaglandin E1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Erectile dysfunction; Female sexual dysfunction; Raynaud's disease

Highest Development Phases

  • Marketed Erectile dysfunction
  • Phase II Raynaud's disease
  • Suspended Female sexual dysfunction
  • No development reported Premature ejaculation; Wounds

Most Recent Events

  • 27 Dec 2016 Launched for Erectile dysfunction in Lebanon (Topical)
  • 26 Oct 2016 Recordati expects to launch Alprostadil topical (Vitaros®) for Erectile dysfunction in Greece, in 1H 2017
  • 26 Oct 2016 Recordati secures approval in Greece for Alprostadil topical (Vitaros®) for Erectile dysfunction
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top